- Home
- TURN vs ATNM Comparison
TURN vs ATNM Comparison
Compare TURN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- ATNM
- Stock Information
- Founded
- TURN 1981
- ATNM 2000
- Country
- TURN United States
- ATNM United States
- Employees
- TURN 8
- ATNM N/A
- Industry
- TURN Finance/Investors Services
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- ATNM Health Care
- Exchange
- TURN Nasdaq
- ATNM Nasdaq
- Market Cap
- TURN 49.6M
- ATNM 50.2M
- IPO Year
- TURN N/A
- ATNM N/A
- Fundamental
- Price
- TURN $4.96
- ATNM $1.63
- Analyst Decision
- TURN
- ATNM Strong Buy
- Analyst Count
- TURN 0
- ATNM 2
- Target Price
- TURN N/A
- ATNM $4.50
- AVG Volume (30 Days)
- TURN 33.1K
- ATNM 134.4K
- Earning Date
- TURN 02-26-2018
- ATNM 11-13-2025
- Dividend Yield
- TURN N/A
- ATNM N/A
- EPS Growth
- TURN N/A
- ATNM N/A
- EPS
- TURN 0.29
- ATNM N/A
- Revenue
- TURN $488,011.00
- ATNM N/A
- Revenue This Year
- TURN N/A
- ATNM N/A
- Revenue Next Year
- TURN N/A
- ATNM N/A
- P/E Ratio
- TURN $17.34
- ATNM N/A
- Revenue Growth
- TURN 277.43
- ATNM N/A
- 52 Week Low
- TURN $3.12
- ATNM $1.03
- 52 Week High
- TURN $5.01
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- TURN 67.09
- ATNM 46.73
- Support Level
- TURN $4.51
- ATNM $1.52
- Resistance Level
- TURN $4.90
- ATNM $1.70
- Average True Range (ATR)
- TURN 0.17
- ATNM 0.07
- MACD
- TURN -0.01
- ATNM -0.01
- Stochastic Oscillator
- TURN 90.00
- ATNM 36.71
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.